Mucosal Lesions Induced in the Rat Intestinal Tract by the Anti-Inflammatory Drug,Wy-41,770,a Weak Inhibitor of Prostaglandin Synthesis,Contrasted with Those from the Potent Prostaglandin Inhibitor,Indomethacin
Free accessResearch articleFirst published online April, 1988
Mucosal Lesions Induced in the Rat Intestinal Tract by the Anti-Inflammatory Drug,Wy-41,770,a Weak Inhibitor of Prostaglandin Synthesis,Contrasted with Those from the Potent Prostaglandin Inhibitor,Indomethacin
The intestinal ulcerogenic activity of the weak prostaglandin synthesis inhibitor drug Wy-41,770 [5H-dibenzo(a,d)-cyclohepten-5-ylidine] was contrasted with the potent synthesis inhibitor, indomethacin, in rats to establish the relationship of inhibition of prostaglandin synthesis to the intestinal damage. Wy-41,770 induced superficial erosions only in the cecum 26 hr after a single oral dose of 250 or 500 mg/kg of the drug, progressing to ulcers after 5 days dosing with ultrastructural evidence of bacteria in the mucosa. Indomethacin (5 or 10 mg/kg po) induced mucosal erosions in the ileum, initially at 26 hr progressing to ulcers after 5 days. Fewer bacteria were seen in the ileal mucosa of indomethacin-treated rats. Both drugs reduced prostaglandin E in those regions of the intestine coincident with the known accumulation of these drugs at sites of mucosal injury. Site-specific intestinal damage from these 2 drugs is associated with inhibition of the synthesis of mucosal-protective prostanoids, followed by pronounced bacterial invasion through the damaged mucosae with consequent appearance of local immuno-inflammatory reactions.
References
1.
1. Anonymous (1983). Withdrawal of Indoprofen. Lancetii: 1436.
2.
2. Antonaci S, Jirillo E, Silvestris F, Llucivero G, Fumarola D, and Bonomo L (1982). In vitro modulation of cell-mediated immunity by prostaglandin E2. I. Enhancing-inhibitory effects of antibody-dependent cellular cytotoxicity. Prostaglandins Leukotrienes Med.9: 285–293.
3.
3. Antonaci S, Jirillo E, Montemurro P, Barbarol L, Bonomo L, and Fumarola D (1982). In vitro modulation of cell-mediated immunity by prostaglandin E2. II. Plaque-forming cell generation. Prostaglandins Leukotrienes Med.9: 295–300.
4.
4. Carlson RP, Datko LJ, Chang J, Nielsen ST, and Lewis AJ (1984). The anti-inflammatory profile of (5-dibenzo-[a,d]-cyclohepten-5-ylidene) acetic acid (Wy-41,770), an agent possessing weak prostaglandin synthesis inhibitory activity that is devoid of gastric side effects. Agents and Actions14: 654–661.
5.
5. Coutrout S, Roland D, Barbier J, Van der Marq P, Alcalay M, and Matuchansky C (1978). Acute perforation of colonic diverticula associated with shortterm indomethacin. Lancetii: 134–139.
6.
6. Davies DR and Brightmore T (1970). Idiopathic and drug-induced ulceration of the small intestine. Br. J. Surg.57: 134–139.
7.
7. Dawson IMP (1983). Atlas of Gastrointestinal Pathology as Seen on Biopsy, Volume 6. MTP Press, Boston.
8.
8. Day TK (1983). Intestinal perforation associated with osmotic slow release indomethacin capsules. Br. Med. J.287: 1671–1672.
9.
9. Duggan DE, Hooke KF, Nool RM, and Kwan KC (1975). Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem. Pharmacol.25: 1749–1754.
10.
10. Editorial (1984). Non-steroidal anti-inflammatory drugs: Have we been spoilt for choice?Lanceti: 141–142.
11.
11. Fang W-F, Broughton A, and Jacobson ED (1970). Indomethacin-induced intestinal inflammation. Dig. Dis. Sci.22: 749–760.
12.
12. Janssen FW, Kirkman SK, Young EM, Schillings RT, Tio CO, Sisenwine SF, and Ruelius HW (1983). Quantitative differences in the rearrangement of 1-O-acyl glucuronides: Implications for the metabolic disposition of carboxylic acids. Proceedings of the First International Symposium on Foreign Compound Metabolism, West Palm Beach, Florida, Oct. 30-Nov. 4, 1983.
13.
13. Kent TH, Cardelli RM, and Stamler FW (1969). Indomethacin-induced intestinal inflammation. Dig. Dis. Sci.22: 749–760.
14.
14. Lewis AJ (1983). Personal communication.
15.
15. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem.193: 265–275.
16.
16. McQueen EG (1981). New Zealand Committee on Adverse Drug Reactions: Fifteenth Annual Report, 1980. N.Z. Med. J.93: 194–198.
17.
17. Pemberton RE and Strand LJ (1979). A review of upper gastro-intestinal effects of newer non-steroidal anti-inflammatory drugs. Dig. Dis. Sci.24: 53–62.
18.
18. Rainsford KD (1975). Electron microscopic observations on the effects of orally administered aspirin and aspirin-bicarbonate mixtures on the development of gastric mucosal damage in the rat.Gut16: 514–527, 1001.
19.
19. Rainsford KD (1982). An analysis of the gastro-intestinal side-effects of non-steroidal anti-inflammatory drugs, with particular reference to comparative studies in man and laboratory species. Rheumatol. Int.2: 1–10.
20.
20. Rainsford KD (1983). Mechanisms of intestinal mucosal damage by non-steroidal anti-inflammatory drugs. In: New Trends in Pathophysiology and Therapy of the Large Bowel, L Barbara, M Miglioli, and SF Phillips (eds). Elsevier, Amsterdam, pp. 207–220.
21.
21. Rainsford KD and Fox SA (1985). Fine structural damage to the intestinal tract induced by two nonsteroidal anti-inflammatory drugs of varying potency as prostaglandin synthesis inhibitors. Abstract, Agents & Actions (1985) 16: 66–68.
22.
22. Rainsford KD, Fox SA, and Osborne DJ (1984). Comparative effects of some non-steroidal anti-inflammatory drugs on the ultrastructurel integrity and prostaglandin levels in the rat gastric mucosa: Relationship to drug uptake. Scand. J. Gastroenterol. (Suppl. 101) 19: 55–68.
23.
23. Reynolds ES (1963). The use of lead citrate at high pH as an electron opaque stain in electron microscopy. J. Cell Biol.17: 208–212.
24.
24. Robert A (1980). Prostaglandins and digestive diseases. In: Advances in Prostaglandin and Thromboxane Research, Volume 8, B Samuelsson, PW Ramwell, and R Paoletti (eds). Raven Press, New York, pp. 1533–1541.
25.
25. Robert A and Asano T (1977). Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins14: 333–341.
26.
26. Ruelius HW, Young EM, Kirkman SK, Schillings RT, Sisenwine SF, and Janssen FW (1985). Biological fate of acyl glucuronides in the rat. The role of rearrangement, intestinal enzymes and reabsorption. Biochem. Pharmacol.34: 2115–2116.
27.
27. Shack MW (1966). Drug induced ulceration and perforation of the small intestine. Arizona Med.23: 517–523.
28.
28. Stewart THM, Hetenyi C, Rowsell H, and Orizaga M (1980). Ulcerative enterocolitis in dogs. Induced by drugs. J. Pathol.131: 363–378.
29.
29. Sturges HF and Krone CL (1973). Ulceration and stricture of the jejunum in a patient on long-term indomethacin therapy. Am. J. Gastroenterol.59: 162–169.
30.
30. Watson ML (1958). Staining of tissue sections for electron microscopy with heavy metals. J. Biophys. Biochem. Cytol.4: 475–478.
31.
31. Wijdeveld PGAB (1971). Some clinical and therapeutic aspects of the nephrotic syndrome in the adult (with special emphasis on the effects of indomethacin and related substances). Folia Med. Neerl.14: 4–31.
